Trials / Completed
CompletedNCT00047801
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 28 (planned)
- Sponsor
- Telik · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLK286 in combination with docetaxel |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2004-09-01
- Completion
- 2004-09-01
- First posted
- 2002-10-21
- Last updated
- 2011-07-25
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00047801. Inclusion in this directory is not an endorsement.